NEW YORK – Merck KGaA on Wednesday said it will stop the Phase III [email protected] Lung 037 trial, within which it was exploring the activity of its investigational bifunctional immunotherapy, bintrafusp alfa, in stage IV non-small lung cancer patients with high PD-L1 expression.